LaFleur & Godfrey LLC lifted its stake in Novartis AG (NYSE:NVS) by 4.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 46,722 shares of the company’s stock after acquiring an additional 1,978 shares during the quarter. LaFleur & Godfrey LLC’s holdings in Novartis were worth $3,923,000 as of its most recent SEC filing.
Other large investors also recently added to or reduced their stakes in the company. Cetera Investment Advisers acquired a new stake in shares of Novartis in the second quarter valued at about $241,000. Bartlett & Co. LLC increased its position in Novartis by 1.6% during the third quarter. Bartlett & Co. LLC now owns 473,081 shares of the company’s stock worth $40,614,000 after buying an additional 7,249 shares during the last quarter. Capital Bank & Trust Co increased its position in Novartis by 5.5% during the third quarter. Capital Bank & Trust Co now owns 138,207 shares of the company’s stock worth $11,865,000 after buying an additional 7,201 shares during the last quarter. Atlantic Trust Group LLC increased its position in Novartis by 54.2% during the third quarter. Atlantic Trust Group LLC now owns 72,427 shares of the company’s stock worth $6,218,000 after buying an additional 25,452 shares during the last quarter. Finally, Cedar Hill Associates LLC acquired a new position in Novartis during the third quarter worth approximately $248,000. 10.85% of the stock is currently owned by institutional investors and hedge funds.
A number of equities analysts have weighed in on the company. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Novartis in a research report on Tuesday, October 24th. Nord/LB reissued a “neutral” rating on shares of Novartis in a research report on Tuesday, January 2nd. Bank of America downgraded Novartis from a “neutral” rating to an “underperform” rating in a research report on Wednesday, December 6th. Leerink Swann boosted their price target on Novartis from $89.00 to $91.00 and gave the stock a “market perform” rating in a research report on Monday, October 23rd. Finally, Zacks Investment Research downgraded Novartis from a “buy” rating to a “hold” rating in a research report on Friday, October 6th. Five research analysts have rated the stock with a sell rating, eight have given a hold rating and four have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $85.32.
Shares of Novartis AG (NYSE:NVS) traded up $0.53 during trading hours on Monday, hitting $86.94. The stock had a trading volume of 770,400 shares, compared to its average volume of 1,047,900. Novartis AG has a 12 month low of $69.53 and a 12 month high of $87.29. The company has a market capitalization of $227,750.00, a PE ratio of 30.94, a PEG ratio of 2.33 and a beta of 0.74. The company has a current ratio of 1.08, a quick ratio of 0.81 and a debt-to-equity ratio of 0.32.
Novartis (NYSE:NVS) last issued its quarterly earnings data on Tuesday, October 24th. The company reported $1.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.25 by $0.04. Novartis had a return on equity of 15.77% and a net margin of 13.73%. The company had revenue of $12.41 billion during the quarter, compared to analysts’ expectations of $12.21 billion. During the same quarter in the previous year, the company posted $1.23 earnings per share. The business’s revenue was up 2.4% on a year-over-year basis. analysts forecast that Novartis AG will post 4.79 earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2018/01/22/lafleur-godfrey-llc-buys-1978-shares-of-novartis-ag-nvs.html.
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.